1064137-33-2 Usage
Uses
Used in Pharmaceutical Industry:
2-(bromomethyl)-3-(2-chlorophenyl)-5-methylquinoxaline is used as a building block for the synthesis of new drugs and biologically active compounds. The presence of the bromomethyl and chlorophenyl groups in the molecule makes it a potential candidate for the development of therapeutic agents.
Used in Materials Science:
2-(bromomethyl)-3-(2-chlorophenyl)-5-methylquinoxaline is used as a component in the development of new materials with specific properties. The quinoxaline structure and its substituents may contribute to the creation of materials with unique characteristics for various applications.
Used in Research and Development:
2-(bromomethyl)-3-(2-chlorophenyl)-5-methylquinoxaline is used as a subject of study for further research into its potential therapeutic applications. 2-(bromomethyl)-3-(2-chlorophenyl)-5-methylquinoxaline's structure and the biological activities associated with the quinoxaline ring make it a valuable candidate for exploring new avenues in drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 1064137-33-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,6,4,1,3 and 7 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1064137-33:
(9*1)+(8*0)+(7*6)+(6*4)+(5*1)+(4*3)+(3*7)+(2*3)+(1*3)=122
122 % 10 = 2
So 1064137-33-2 is a valid CAS Registry Number.
1064137-33-2Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS AND THEIR USES
-
, (2008/12/04)
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on, or associated with p110 activity, including but not restricted to leukemias, such as acute myeloid leukaemia (AML), myelo-dysplastic syndrome (MDS), myelo-proliferative diseases (MPD), chronic myeloid leukemia (CML), T-cell acute lymphoblastic leukaemia (T-ALL), B-cell acute lymphoblastic leukaemia (B-ALL), non Hodgkins lymphoma (NHL), B-cell lymphoma and solid tumors, such as breast cancer.
